Ironwood Pharmaceuticals Inc – Class A (NASDAQ:IRWD) Can’t Be More Risky. Short Interest Increased

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Investors sentiment increased to 1.63 in 2019 Q2. Its up 0.26, from 1.37 in 2019Q1. It increased, as 20 investors sold Ironwood Pharmaceuticals, Inc. shares while 26 reduced holdings. 21 funds opened positions while 54 raised stakes. 149.39 million shares or 1.83% more from 146.70 million shares in 2019Q1 were reported.
Art Advsrs Ltd holds 123,571 shares. Amalgamated Fincl Bank stated it has 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Canada Pension Plan Invest Board holds 130,600 shares or 0% of its portfolio. 15,910 are owned by Fin Counselors. Great West Life Assurance Can has 19,792 shares for 0% of their portfolio. 90,293 were accumulated by Morgan Stanley. Natl Bank Of Montreal Can stated it has 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Northern Corporation accumulated 1.79 million shares or 0% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) reported 8,452 shares stake. 22,425 were reported by Evercore Wealth Limited Liability Corp. Bank Of New York Mellon stated it has 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). State Board Of Administration Of Florida Retirement Systems invested in 0% or 89,266 shares. Employees Retirement Association Of Colorado stated it has 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). State Street Corp holds 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 6.14M shares. 10,335 were accumulated by Numerixs Investment Technologies Incorporated.

The stock of Ironwood Pharmaceuticals Inc – Class A (NASDAQ:IRWD) registered an increase of 4.04% in short interest. IRWD’s total short interest was 17.70 million shares in September as published by FINRA. Its up 4.04% from 17.01M shares, reported previously. With 1.39 million shares average volume, it will take short sellers 13 days to cover their IRWD’s short positions.

The stock decreased 0.52% or $0.05 during the last trading session, reaching $9.6. About 2.04 million shares traded or 10.83% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 32.56% since September 13, 2018 and is downtrending. It has underperformed by 32.56% the S&P500.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $1.50 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 3 analysts covering Ironwood Pharma (NASDAQ:IRWD), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Ironwood Pharma has $16 highest and $13 lowest target. $14.33’s average target is 49.27% above currents $9.6 stock price. Ironwood Pharma had 5 analyst reports since March 22, 2019 according to SRatingsIntel. Morgan Stanley upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, March 27 to “Equal-Weight” rating. H.C. Wainwright maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Monday, June 24. H.C. Wainwright has “Hold” rating and $13 target. The firm earned “Hold” rating on Friday, March 22 by Credit Suisse.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Nasdaq.com which released: “Investors Can Find Big Returns with this First Profit Screen – Nasdaq” on September 10, 2019, also Nasdaq.com with their article: “Ardelyx (ARDX) Gains on Tenapanor’s Success in Pivotal Study – Nasdaq” published on September 04, 2019, Seekingalpha.com published: “Ironwood Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” on February 12, 2019. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Nasdaq.com and their article: “Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall – Nasdaq” published on May 03, 2019 as well as Seekingalpha.com‘s news article titled: “Ironwood completes Cyclerion spin-off – Seeking Alpha” with publication date: April 01, 2019.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.